IML-206
SARS-CoV-2 / Coronavirus Infection
Pre-clinicalActive
Key Facts
About Immunologik
ImmunoLogik is a private, preclinical-stage biotech developing host-targeted antivirals for HIV and coronaviruses. Its lead candidates, IML-106 for HIV and IML-206 for SARS-CoV-2/other coronaviruses, aim to block essential cellular pathways used by viruses for replication, potentially reducing the risk of drug resistance. The company leverages strong academic ties, notably with the University Hospital Erlangen, and is supported by the strategic and operational expertise of the Athenion Group. It is currently pre-revenue and focused on advancing its pipeline through preclinical development.
View full company profile